Moomoo AI 已提取核心訊息
CRISPR Therapeutics AG, a biotechnology company, has entered into a significant investment agreement with certain institutional investors on February 13, 2024. The agreement involves the issuance of 3,916,082 common shares at a par value of CHF 0.03 per share, with the shares being offered at a price of $71.50 each. This offering is expected to generate gross proceeds of approximately $280 million before the deduction of estimated offering expenses. The transaction is supported by a shelf registration statement previously filed with the SEC on July 29, 2021. The investment agreement includes standard representations, warranties, closing conditions, termination clauses, and indemnification obligations. The details of the agreement are disclosed in the company's Form 8-K filing with the SEC, along with the legal opinion of Walder Wyss AG regarding the share issuance.
CRISPR Therapeutics AG, a biotechnology company, has entered into a significant investment agreement with certain institutional investors on February 13, 2024. The agreement involves the issuance of 3,916,082 common shares at a par value of CHF 0.03 per share, with the shares being offered at a price of $71.50 each. This offering is expected to generate gross proceeds of approximately $280 million before the deduction of estimated offering expenses. The transaction is supported by a shelf registration statement previously filed with the SEC on July 29, 2021. The investment agreement includes standard representations, warranties, closing conditions, termination clauses, and indemnification obligations. The details of the agreement are disclosed in the company's Form 8-K filing with the SEC, along with the legal opinion of Walder Wyss AG regarding the share issuance.
生物技術公司CRISPR Therapeutics AG已於2024年2月13日與某些機構投資者簽訂了一項重大投資協議。該協議涉及發行3,916,082股普通股，面值爲每股0.03瑞士法郎，每股發行價格爲71.50美元。在扣除預計的發行費用之前，此次發行預計將產生約2.8億美元的總收益。該交易得到了先前於2021年7月29日向美國證券交易委員會提交的貨架註冊聲明的支持。投資協議包括標準陳述、擔保、成交條件、終止條款和賠償義務。該協議的細節在該公司向美國證券交易委員會提交的8-K表格以及Walder Wyss AG關於股票發行的法律意見書中披露。
生物技術公司CRISPR Therapeutics AG已於2024年2月13日與某些機構投資者簽訂了一項重大投資協議。該協議涉及發行3,916,082股普通股，面值爲每股0.03瑞士法郎，每股發行價格爲71.50美元。在扣除預計的發行費用之前，此次發行預計將產生約2.8億美元的總收益。該交易得到了先前於2021年7月29日向美國證券交易委員會提交的貨架註冊聲明的支持。投資協議包括標準陳述、擔保、成交條件、終止條款和賠償義務。該協議的細節在該公司向美國證券交易委員會提交的8-K表格以及Walder Wyss AG關於股票發行的法律意見書中披露。
有用
沒用